The Latest
-
Brian Tucker / BioPharma Dive/BioPharma Dive
The biopharma industry outlook on 2026: Optimism and tension
A spike in M&A activity and stock prices have pulled biotech out of a yearslong downturn. But regulatory tumult and fierce competition from China could short-circuit the sector's resurgence.
-
Permission granted by Catalent
Sponsored by CatalentThe crucial role of raw material selection for success in cell therapy manufacturing
Why raw materials make or break cell therapy manufacturing success.
-
Kevin Frayer via Getty Images
China competitionDrugs from China are reshaping biotech. Track the licensing deals here.
Startup Formation Bio is paying up to $500 million for a prospect with the same mechanism as AbiVax’s closely watched inflammatory bowel disease drug obefazimod.
Updated 13 hours ago -
Getty Images
Gene editingLilly bets on Seamless, delving further into genetic medicine for hearing loss
The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge treatments the company is developing for hearing disorders.
-
anouchka via Getty Images
Deep Dive5 questions facing biopharma in 2026
The biopharmaceutical sector finally regained its footing in 2025. Here are five issues that could determine whether the renewed optimism will carry over into the new year.
-
Getty Images
Trump administrationDrugs for cancer, arthritis and HIV on Medicare’s list for 2028 price cuts
Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — draw very limited revenue from Medicare, an analyst pointed out.
-
Kevin Frayer via Getty Images
China competitionChina’s edge in early-stage drugmaking ‘likely to persist,’ Pitchbook says
The ongoing surge in licensing deals for early drug prospects should continue this year and involve more cell and gene therapies, which have had trouble securing funding in the U.S., the firm said in a new report.
-
Adeline Kon/BioPharma Dive
Deep Dive // IPO windowBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
Eikon Therapeutics outlined terms for an IPO that could be worth up to $317 million. Elsewhere, a liver disease-focused spinout of BioVie joined the queue.
Updated Jan. 28, 2026 -
Getty Images
News roundupHalozyme buys a biotech startup; Cytokinetics launches heart drug
Halozyme is paying as much as $400 million for a drug delivery specialist that could boost its growth prospects, one analyst wrote. Elsewhere, Boehringer dipped into China for a bispecific drug and a trans-Atlantic VC firm restocked.
-
Courtesy of Intellia Therapeutics
Gene editingFDA lifts hold on an Intellia CRISPR drug trial
Intellia is instituting new safeguards following the death of a study participant that led regulators to pause two trials in people with transthyretin amyloidosis. One of those tests remains suspended.
-
Permission granted by TRex Bio
An immune drug developer raises $50M to finance its eczema drug testing
TRex Bio banked a Series B extension to advance its atopic dermatitis program, which is competing in a crowded field.
-
Jacob Bell/BioPharma Dive
Sarepta, battling slowing sales, claims Duchenne gene therapy’s impact grows with time
On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help “rebalance the discussion” surrounding Elevidys.
-
Spencer Platt via Getty Images
IPO windowBiotech investor Cormorant secures $150M for another SPAC deal
Amid a rebound in SPAC activity, the prolific “crossover” investor is aiming for its third blank-check merger since 2022 following deals with Moonlake Immunotherapeutics and BridgeBio Oncology Therapeutics.
-
Permission granted by Sanofi
Sanofi to seek approval of touted eczema drug despite mixed results
Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U.S. but has murky sales prospects.
-
Getty Images
News roundup
Novo climbs higher on ‘strong’ Wegovy pill launch; Terns tweaks leukemia drug deal
Novo shares have surged more than 20% amid oral Wegovy’s fast start. Elsewhere, Terns opened up room for a potential partnership and Corcept solidified its case for an ovarian cancer drug.
-
Leigh Vogel via Getty Images
Express Scripts considering settlement in FTC insulin price lawsuit
The antitrust agency paused its lawsuit against the pharmacy benefit manager while the two discuss a proposed consent agreement.
-
Getty Images
Startup launchesBioMarin vets form Mendra to ‘modernize’ rare disease drug development
Backed with $82 million and led by two of BioMarin’s former executives, Mendra plans to acquire rare disease assets and use AI to help accelerate their development.
-
Win McNamee via Getty Images
Congress eyes tackling healthcare consolidation
“I think there’s common ground here,” one Republican congressman said Wednesday during a House Budget Committee hearing. Squaring up against healthcare monopolies would be a major pivot for the GOP.
-
Jacob Bell/BioPharma Dive
Emerging biotechOn biotech’s biggest stage, renewed excitement gets a stress test
A surge in deals and financings had the industry abuzz heading into this year’s J.P. Morgan Healthcare Conference. But some aren’t sure if the rebound is here to stay.
-
Getty Images
China competitionInvestors load Corxel with $287M for a ‘differentiated’ obesity pill
The funding will support a GLP-1 pill Corxel licensed from China-based Vincentage in 2024 and that the company believes to be as effective in spurring weight loss as injectable therapies.
-
Alamy
FDA lays out new path to speed development of multiple myeloma drugs
In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change that could accelerate cell therapies and other new medicines.
-
Courtesy of Johnson & Johnson
J&J eyes $100B in sales amid gains for cancer, immune drugs
Amid patent expirations, litigation and tariff costs, J&J says it expects more growth ahead, fueled in part by its blood cancer medicines and a closely watched psoriasis pill.
-
Courtesy of BMS
Bristol Myers buys into Janux’s ‘masked’ T cell engagers
Worth up to $850 million, the partnership provides “further validation” for Janux at a time of heightened investor scrutiny regarding the potential of its top drug, one analyst wrote.
-
Getty Images
Corvus shares nearly triple on positive data for eczema pill
While early, the results indicate drugs known as ITK inhibitors have the potential to match or surpass the efficacy observed with the injectable biologic Dupixent.
-
Permission granted by Kailera Therapeutics
Q&A // Emerging biotechKailera’s Ron Renaud on how a China-linked startup can compete in obesity
In an interview with BioPharma Dive, the veteran biotech CEO said there remains a “significant opportunity” for young companies in a market dominated by Novo Nordisk and Eli Lilly.
-
Permission granted by GSK
GSK to buy Rapt in $2.2B deal for food allergy drug
The deal is the first for new CEO Luke Miels as the British drugmaker looks to overcome pressure on its HIV and vaccines businesses.
